Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.39
+0.30 (+0.27%)
Streaming Delayed Price
Updated: 1:53 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
19
20
Next >
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
February 17, 2023
From
Merck & Co., Inc.
Via
Business Wire
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
February 16, 2023
Animal health company Zoetis is up 7.99% in the past week, after topping fourth-quarter views. Analysts see double-digit EPS growth in 2023 and 2024.
Via
MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
February 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 2/6 - 2/10
February 11, 2023
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Should Investors Buy or Sell the Vaccinex Patent News?
February 07, 2023
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
February 07, 2023
Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in
Via
MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
February 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
February 02, 2023
From
Merck & Co., Inc.
Via
Business Wire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
January 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
January 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
January 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
January 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Via
MarketBeat
Merck Announces Second-Quarter 2023 Dividend
January 24, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
January 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
January 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
January 05, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Big Health Care Stocks to Watch in the New Year
December 29, 2022
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
Via
MarketBeat
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
December 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
December 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
December 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
December 20, 2022
From
Seagen Inc.
Via
Business Wire
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
December 15, 2022
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
December 13, 2022
Via
ACCESSWIRE
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
December 12, 2022
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.